{"hands_on_practices": [{"introduction": "Before a drug can exert its effect, it must first bind to its molecular target. This exercise [@problem_id:2865631] provides practice in applying one of the most fundamental principles of pharmacology—receptor occupancy—to the context of an anti-CD47 antibody. By working through this problem, you will solidify your understanding of how the dissociation constant ($K_d$) and local drug concentration determine the fraction of target receptors engaged, a crucial first step in predicting a drug's therapeutic activity and a key concept in macrophage checkpoint blockade.", "problem": "A biotechnology group is developing a monoclonal antibody (mAb) that blocks cluster of differentiation 47 (CD47) to disrupt the CD47–signal regulatory protein alpha (SIRPα) axis in macrophage checkpoint blockade. Consider a single class of noncooperative binding sites and a one-to-one interaction between CD47 and the mAb. Assume rapid binding relative to pharmacokinetic timescales so that a local binding equilibrium can be invoked at the site of action, and assume that the free mAb concentration is much larger than the concentration of unbound receptor so that the measured free mAb concentration is not substantially perturbed by binding. Define receptor occupancy as a quantitative property of this system and identify the correct functional dependence of receptor occupancy on free mAb concentration under these assumptions. Then, apply this relationship to compute the expected CD47 occupancy in the tumor interstitium given the following data collected at steady state during dosing: plasma free mAb concentration is $6$ nM, tumor interstitial free mAb concentration is $2$ nM, and the dissociation constant for mAb–CD47 binding is $2$ nM. Which option below is fully correct in its definition, relationship, numerical evaluation, and interpretation of the role of plasma versus interstitial concentrations?\n\nA. Receptor occupancy is the fraction of signal regulatory protein alpha (SIRPα) molecules on macrophages bound by the anti-CD47 mAb; at equilibrium it varies inversely with mAb concentration as $f=\\dfrac{K_d}{C+K_d}$; using the plasma concentration yields $f=\\dfrac{2}{6+2}=0.25$; plasma concentrations equal interstitial concentrations at steady state, so plasma is always a valid surrogate for occupancy at the site of action.\n\nB. Receptor occupancy is the fraction of CD47 molecules at the site of action that are bound by the anti-CD47 mAb; at equilibrium with one-to-one, noncooperative binding it is $f=\\dfrac{C}{C+K_d}$, where $C$ is the free mAb concentration at the receptor microenvironment; using the tumor interstitial concentration gives $f=\\dfrac{2}{2+2}=0.50$; plasma free mAb may not be a valid surrogate for occupancy when distributional gradients or target-mediated sinks create differences between plasma and interstitial free concentrations.\n\nC. Receptor occupancy is the fraction of signal regulatory protein alpha (SIRPα) molecules whose inhibitory signaling is blocked; due to avidity effects the proper relationship is $f=\\dfrac{C^2}{C^2+K_d^2}$; using the plasma concentration yields $f=\\dfrac{6^2}{6^2+2^2}=0.90$; ongoing receptor internalization at steady state invalidates any equilibrium-based occupancy calculation.\n\nD. Receptor occupancy is the fraction of CD47 molecules bound by the anti-CD47 mAb; because the on-rate dominates at steady state, $f=\\dfrac{C}{K_d}$ until saturation; using the tumor interstitial concentration gives $f=\\dfrac{2}{2}=1.0$; therefore plasma and interstitial concentrations are interchangeable for occupancy estimation as long as dosing is continuous.", "solution": "The problem requires an evaluation of receptor occupancy for a monoclonal antibody (mAb) targeting cluster of differentiation 47 (CD47). I will first validate the problem statement and then, finding it valid, derive the correct relationship for receptor occupancy from first principles and evaluate each option.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n- **Therapeutic Agent:** A monoclonal antibody (mAb) that blocks CD47.\n- **Target Interaction:** Disrupts the CD47–signal regulatory protein alpha (SIRPα) axis.\n- **Binding Assumptions:**\n    1.  A single class of noncooperative binding sites.\n    2.  A one-to-one ($1:1$) interaction between CD47 and the mAb.\n    3.  Rapid binding relative to pharmacokinetic timescales, allowing for a local binding equilibrium assumption at the site of action.\n    4.  Free mAb concentration is much larger than the concentration of unbound receptor, thus the free mAb concentration is not significantly depleted by binding.\n- **Data at Steady State:**\n    -   Plasma free mAb concentration: $C_{plasma} = 6$ nM.\n    -   Tumor interstitial free mAb concentration: $C_{interstitial} = 2$ nM.\n    -   Dissociation constant for mAb–CD47 binding: $K_d = 2$ nM.\n- **Question:** Identify the correct statement regarding the definition of receptor occupancy, its functional dependence on mAb concentration, its numerical value, and the interpretation of plasma versus interstitial concentrations.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is firmly grounded in the principles of pharmacology, immunology, and biophysical chemistry. The CD47-SIRPα axis is a well-established target in immuno-oncology. The concepts of receptor occupancy, dissociation constant ($K_d$), local equilibrium, and pharmacokinetic concentration gradients between plasma and tissue are standard and fundamental in drug development. The problem is scientifically sound.\n- **Well-Posedness:** The problem provides a clear set of assumptions (noncooperative, $1:1$ binding, local equilibrium) and all necessary parameters ($K_d$ and relevant concentrations) to calculate a unique value for receptor occupancy at the site of action.\n- **Objectivity:** The problem is stated in precise, objective, and technical language, free from ambiguity or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem statement is scientifically sound, well-posed, and objective. It is **valid**. I will proceed to derive the solution.\n\n**Derivation of the Solution**\n\nLet $R$ represent the receptor (CD47), $L$ represent the ligand (the anti-CD47 mAb), and $RL$ represent the bound complex. The binding reaction is:\n$$R + L \\rightleftharpoons RL$$\nBy definition, the dissociation constant, $K_d$, at equilibrium is given by:\n$$K_d = \\frac{[R][L]}{[RL]}$$\nwhere $[...]$ denotes the molar concentration of the species.\n\nReceptor occupancy, denoted by $f$, is defined as the fraction of the total receptor population that is bound by the ligand. The total receptor concentration, $[R_{total}]$, is the sum of the free receptor concentration, $[R]$, and the bound receptor concentration, $[RL]$:\n$$[R_{total}] = [R] + [RL]$$\nThe occupancy $f$ is therefore:\n$$f = \\frac{[RL]}{[R_{total}]} = \\frac{[RL]}{[R] + [RL]}$$\nTo express $f$ as a function of the free ligand concentration $[L]$ and $K_d$, we first rearrange the $K_d$ expression to solve for $[R]$:\n$$[R] = \\frac{K_d [RL]}{[L]}$$\nSubstituting this into the occupancy equation:\n$$f = \\frac{[RL]}{\\frac{K_d [RL]}{[L]} + [RL]}$$\nThe term $[RL]$ appears in the numerator and in both terms of the denominator, so it can be cancelled:\n$$f = \\frac{1}{\\frac{K_d}{[L]} + 1}$$\nMultiplying the numerator and denominator by $[L]$ yields the standard Hill-Langmuir equation for noncooperative, $1:1$ binding:\n$$f = \\frac{[L]}{[L] + K_d}$$\nThe problem asks for receptor occupancy at the site of action, which is the tumor. Therefore, the relevant free ligand concentration is the tumor interstitial free mAb concentration. Let us denote the free mAb concentration as $C$. The correct concentration to use is $C = C_{interstitial} = 2$ nM. The dissociation constant is given as $K_d = 2$ nM.\n\nWe can now compute the receptor occupancy:\n$$f = \\frac{C_{interstitial}}{C_{interstitial} + K_d} = \\frac{2 \\text{ nM}}{2 \\text{ nM} + 2 \\text{ nM}} = \\frac{2}{4} = 0.50$$\nThus, the expected receptor occupancy in the tumor interstitium is $50\\%$.\n\nThe problem also presents two different concentrations: plasma ($6$ nM) and tumor interstitial ($2$ nM). This difference is expected for a large molecule like an mAb due to transport limitations across the endothelium into the tumor tissue. Because binding occurs in the tumor, the interstitial concentration is the only relevant one for calculating occupancy at the target site. The plasma concentration serves as a systemic measure but is not a direct surrogate for target engagement in the tissue, especially when a significant gradient exists.\n\n**Evaluation of Options**\n\n**A. Receptor occupancy is the fraction of signal regulatory protein alpha (SIRPα) molecules on macrophages bound by the anti-CD47 mAb; at equilibrium it varies inversely with mAb concentration as $f=\\dfrac{K_d}{C+K_d}$; using the plasma concentration yields $f=\\dfrac{2}{6+2}=0.25$; plasma concentrations equal interstitial concentrations at steady state, so plasma is always a valid surrogate for occupancy at the site of action.**\n- **Definition:** **Incorrect**. The mAb is an anti-CD47 antibody, meaning it binds to CD47, not SIRPα.\n- **Relationship:** **Incorrect**. The formula $f=\\dfrac{K_d}{C+K_d}$ is mathematically incorrect for receptor occupancy.\n- **Calculation:** **Incorrect**. The calculation uses the wrong concentration (plasma, $6$ nM) instead of the local interstitial concentration ($2$ nM).\n- **Interpretation:** **Incorrect**. The statement that plasma equals interstitial concentrations at steady state is factually wrong and is directly contradicted by the data provided ($6$ nM $\\neq$ $2$ nM).\nVerdict: **Incorrect**.\n\n**B. Receptor occupancy is the fraction of CD47 molecules at the site of action that are bound by the anti-CD47 mAb; at equilibrium with one-to-one, noncooperative binding it is $f=\\dfrac{C}{C+K_d}$, where $C$ is the free mAb concentration at the receptor microenvironment; using the tumor interstitial concentration gives $f=\\dfrac{2}{2+2}=0.50$; plasma free mAb may not be a valid surrogate for occupancy when distributional gradients or target-mediated sinks create differences between plasma and interstitial free concentrations.**\n- **Definition:** **Correct**. It correctly identifies occupancy as the fraction of bound CD47 molecules.\n- **Relationship:** **Correct**. It presents the correct Hill-Langmuir equation, $f=\\dfrac{C}{C+K_d}$, consistent with the problem's assumptions and correctly identifies $C$ as the local concentration.\n- **Calculation:** **Correct**. It uses the appropriate concentration (tumor interstitial, $2$ nM) and performs the calculation accurately: $f = \\frac{2}{2+2} = 0.50$.\n- **Interpretation:** **Correct**. It accurately explains why plasma concentration may not be a valid surrogate for target occupancy due to pharmacokinetic gradients, which is consistent with the provided data.\nVerdict: **Correct**.\n\n**C. Receptor occupancy is the fraction of signal regulatory protein alpha (SIRPα) molecules whose inhibitory signaling is blocked; due to avidity effects the proper relationship is $f=\\dfrac{C^2}{C^2+K_d^2}$; using the plasma concentration yields $f=\\dfrac{6^2}{6^2+2^2}=0.90$; ongoing receptor internalization at steady state invalidates any equilibrium-based occupancy calculation.**\n- **Definition:** **Incorrect**. This describes a pharmacodynamic endpoint (signaling blockade), not receptor occupancy (target binding). It also misidentifies the mAb target as SIRPα.\n- **Relationship:** **Incorrect**. The formula $f=\\dfrac{C^2}{C^2+K_d^2}$ describes cooperative binding (Hill coefficient of $2$), which is explicitly ruled out by the \"noncooperative\" assumption. It also incorrectly invokes avidity, which is contrary to the \"one-to-one interaction\" assumption.\n- **Calculation:** **Incorrect**. It uses the wrong formula and the wrong concentration.\n- **Interpretation:** **Incorrect**. The statement that internalization invalidates the equilibrium assumption is a strong claim that contradicts the explicit instruction in the problem to \"invoke a local binding equilibrium\". The quasi-equilibrium assumption is a standard and useful approximation in pharmacology, even in the presence of dynamic processes like internalization.\nVerdict: **Incorrect**.\n\n**D. Receptor occupancy is the fraction of CD47 molecules bound by the anti-CD47 mAb; because the on-rate dominates at steady state, $f=\\dfrac{C}{K_d}$ until saturation; using the tumor interstitial concentration gives $f=\\dfrac{2}{2}=1.0$; therefore plasma and interstitial concentrations are interchangeable for occupancy estimation as long as dosing is continuous.**\n- **Definition:** **Correct**.\n- **Relationship:** **Incorrect**. The formula $f=\\dfrac{C}{K_d}$ is a linear approximation valid only for $C \\ll K_d$. It is not a general formula. The reasoning \"because the on-rate dominates at steady state\" is scientifically nonsensical; at steady state, the on-rate equals the off-rate by definition.\n- **Calculation:** **Incorrect**. The calculation uses the flawed linear approximation, leading to an incorrect result of $1.0$. The correct occupancy is $0.50$.\n- **Interpretation:** **Incorrect**. The conclusion that plasma and interstitial concentrations are interchangeable is a non-sequitur and is factually refuted by the problem's own data. Continuous dosing maintains a steady state but does not eliminate the biophysical barriers that cause concentration gradients.\nVerdict: **Incorrect**.\n\nIn conclusion, only option B is correct in all its parts.", "answer": "$$\\boxed{B}$$", "id": "2865631"}, {"introduction": "A major challenge in developing therapies against targets like CD47, which are also expressed on healthy cells, is the \"antigen sink\" effect. This practice [@problem_id:2865634] offers a tangible, quantitative look at this phenomenon by guiding you through a first-principles calculation of the antibody mass required to saturate CD47 on the entire red blood cell population. This back-of-the-envelope calculation is a powerful tool for appreciating the pharmacological burden imposed by a large peripheral antigen sink and why it is a critical consideration in drug development.", "problem": "A therapeutic anti-cluster of differentiation 47 (CD47) checkpoint blockade strategy must consider the sink effect of red blood cells (RBCs). Assume a human subject has $2.5 \\times 10^{13}$ circulating red blood cells (RBCs), each expressing $1.0 \\times 10^{6}$ accessible CD47 epitopes. To estimate the antibody requirement for full occupancy of these epitopes by an anti-CD47 Immunoglobulin G (IgG), proceed from first principles as follows: use the definition of Avogadro’s number $N_{A}$ (the number of molecules per mole), the definition of molar mass, and a stoichiometric $1{:}1$ binding model in which each CD47 epitope is occupied by one IgG molecule (assume bivalent binding does not reduce molecular demand due to steric and spatial constraints on the red blood cell surface). The IgG has a molar mass of $150\\,\\mathrm{kDa}$, where $1\\,\\mathrm{kDa} = 10^{3}\\,\\mathrm{g/mol}$. Use $N_{A} = 6.022 \\times 10^{23}\\,\\mathrm{mol^{-1}}$. \n\nCompute the total CD47 binding site burden on RBCs and, using Avogadro’s number, estimate the mass of IgG required to fully occupy these sites at $1{:}1$ stoichiometry. Express the final mass in grams and round your answer to three significant figures. Report only the IgG mass in grams as your final numerical answer.", "solution": "The problem statement is subjected to validation before a solution is attempted.\n\nStep 1: Extracted Givens.\n- Number of circulating red blood cells (RBCs): $N_{RBC} = 2.5 \\times 10^{13}$\n- Number of accessible CD47 epitopes per RBC: $N_{epitope/RBC} = 1.0 \\times 10^{6}$\n- Binding stoichiometry: $1{:}1$ (one IgG molecule per one CD47 epitope)\n- Molar mass of IgG: $M_{IgG} = 150\\,\\mathrm{kDa}$\n- Molar mass unit conversion: $1\\,\\mathrm{kDa} = 10^{3}\\,\\mathrm{g/mol}$\n- Avogadro’s number: $N_{A} = 6.022 \\times 10^{23}\\,\\mathrm{mol^{-1}}$\n- Objective: Compute the mass of IgG required for full occupancy of all CD47 sites on RBCs.\n- Reporting requirement: Express the final mass in grams, rounded to three significant figures.\n\nStep 2: Validation.\nThe problem is scientifically grounded, as it addresses the real-world pharmacological concept of an \"antigen sink\" in antibody-based therapies. The provided numerical values for RBC count, CD47 receptor density, IgG molar mass, and Avogadro's constant are standard and factually correct within the context of human biology and chemistry. The problem is well-posed, providing all necessary information for a unique solution. The language is objective and precise. The problem does not violate any of the specified invalidity criteria.\n\nStep 3: Verdict.\nThe problem is valid. A rigorous solution will now be derived from first principles.\n\nThe logical procedure is as follows: first, determine the total number of target binding sites (CD47 epitopes) in the system. Second, use the specified stoichiometry to determine the total number of antibody molecules required. Third, convert this number of molecules into moles using Avogadro's number. Finally, calculate the required mass using the molar mass of the antibody.\n\nLet $N_{total\\_sites}$ be the total number of CD47 binding sites on the entire population of RBCs. This is calculated by multiplying the number of RBCs by the number of epitopes per RBC.\n$$N_{total\\_sites} = N_{RBC} \\times N_{epitope/RBC}$$\n$$N_{total\\_sites} = (2.5 \\times 10^{13}) \\times (1.0 \\times 10^{6}) = 2.5 \\times 10^{19}$$\nThis represents the total number of individual binding targets.\n\nAccording to the problem's assumption of a $1{:}1$ binding stoichiometry, one IgG molecule is required for each CD47 epitope. Therefore, the total number of IgG molecules, $N_{IgG}$, required for full saturation is equal to the total number of sites.\n$$N_{IgG} = N_{total\\_sites} = 2.5 \\times 10^{19}$$\n\nNext, we convert this number of molecules into the corresponding amount in moles, denoted by $n_{IgG}$. This is accomplished by dividing the total number of molecules by Avogadro's number, $N_{A}$.\n$$n_{IgG} = \\frac{N_{IgG}}{N_{A}}$$\n$$n_{IgG} = \\frac{2.5 \\times 10^{19}}{6.022 \\times 10^{23}\\,\\mathrm{mol^{-1}}}$$\n\nThe molar mass of the IgG, $M_{IgG}$, is given as $150\\,\\mathrm{kDa}$. We must convert this into standard units of grams per mole ($\\mathrm{g/mol}$).\n$$M_{IgG} = 150\\,\\mathrm{kDa} = 150 \\times 10^{3}\\,\\mathrm{g/mol} = 1.5 \\times 10^{5}\\,\\mathrm{g/mol}$$\n\nFinally, the total mass of IgG, $m_{IgG}$, is the product of the number of moles and the molar mass.\n$$m_{IgG} = n_{IgG} \\times M_{IgG}$$\n$$m_{IgG} = \\left( \\frac{2.5 \\times 10^{19}}{6.022 \\times 10^{23}\\,\\mathrm{mol^{-1}}} \\right) \\times (1.5 \\times 10^{5}\\,\\mathrm{g/mol})$$\nWe perform the calculation:\n$$m_{IgG} = \\frac{2.5 \\times 1.5}{6.022} \\times \\frac{10^{19} \\times 10^{5}}{10^{23}}\\,\\mathrm{g}$$\n$$m_{IgG} = \\frac{3.75}{6.022} \\times 10^{19+5-23}\\,\\mathrm{g}$$\n$$m_{IgG} = \\frac{3.75}{6.022} \\times 10^{1}\\,\\mathrm{g}$$\n$$m_{IgG} \\approx 0.6227166 \\times 10\\,\\mathrm{g}$$\n$$m_{IgG} \\approx 6.227166\\,\\mathrm{g}$$\n\nThe problem requires the final answer to be rounded to three significant figures.\n$$m_{IgG} \\approx 6.23\\,\\mathrm{g}$$\nThis mass represents the theoretical minimum dose required to saturate only the CD47 antigen sink presented by the red blood cell compartment.", "answer": "$$\\boxed{6.23}$$", "id": "2865634"}, {"introduction": "To overcome the toxicity challenges posed by antigen sinks, immunologists and engineers design therapeutics with enhanced selectivity for cancer cells. This problem [@problem_id:2865629] explores a powerful strategy: a bispecific antibody designed with different affinities for a tumor antigen versus the off-tumor CD47 target. By analyzing the occupancy of both targets as a function of drug concentration, you will learn to quantitatively define a \"therapeutic window\" and appreciate how narrow it can be, highlighting the elegant but demanding precision required in modern drug design.", "problem": "In macrophage checkpoint blockade against cancer, a common strategy to minimize on-target, off-tumor toxicity is to construct a bispecific molecule that binds a tumor-associated antigen with high affinity while concurrently blocking a macrophage inhibitory axis such as Cluster of Differentiation 47 (CD47) to Signal Regulatory Protein alpha (SIRPα) engagement. Red Blood Cells (RBC) express CD47, so excessive binding of the CD47-blocking arm to RBC can lead to anemia due to increased erythrophagocytosis. Consider a bispecific molecule with a dissociation constant to the tumor-associated antigen of $K_{d}^{\\text{tumor}} = 0.1\\,\\text{nM}$ and an apparent dissociation constant for monovalent binding to CD47 on RBC of $K_{d}^{\\text{RBC}} = 10\\,\\text{nM}$. Assume a single-site reversible binding equilibrium and that, over the concentration range of interest, the free drug concentration is approximately equal to the total drug concentration in plasma. Define the fold-selectivity in affinity for tumor over RBC as the ratio $S = K_{d}^{\\text{RBC}}/K_{d}^{\\text{tumor}}$.\n\nStarting from the equilibrium definition of the dissociation constant and the standard single-site binding occupancy model, first compute $S$. Then, using the same binding framework, evaluate whether there exists a free drug concentration at which the fractional occupancy on RBC remains below $0.1$ while the occupancy on tumor reaches or exceeds $0.9$. Clearly state your reasoning about the consequences for dosing to avoid anemia in the setting of macrophage checkpoint blockade.\n\nFor the final answer, report only the numerical value of $S$ as a dimensionless quantity. No rounding is required. Do not include units in your final answer.", "solution": "The problem will be validated before any attempt at a solution is made.\n\nStep 1: Extract Givens\n- Dissociation constant to tumor-associated antigen: $K_{d}^{\\text{tumor}} = 0.1\\,\\text{nM}$\n- Apparent dissociation constant for monovalent binding to CD47 on Red Blood Cells (RBC): $K_{d}^{\\text{RBC}} = 10\\,\\text{nM}$\n- Binding model: single-site reversible binding equilibrium.\n- Assumption: free drug concentration is approximately equal to the total drug concentration, $[D]$.\n- Definition of fold-selectivity: $S = K_{d}^{\\text{RBC}}/K_{d}^{\\text{tumor}}$\n- Condition for RBC: fractional occupancy $\\theta_{\\text{RBC}} < 0.1$\n- Condition for tumor: fractional occupancy $\\theta_{\\text{tumor}} \\ge 0.9$\n\nStep 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in standard principles of receptor pharmacology and immunology. The concepts of dissociation constants, fractional occupancy, and therapeutic selectivity are fundamental to drug development. The provided values for the dissociation constants are physically realistic for biomolecular interactions. The problem is well-posed, providing all necessary information and clear definitions to perform the required calculations and analysis. The language is objective and precise. The problem does not violate any of the specified criteria for invalidity. It is a formalizable and solvable problem within the scope of biophysical chemistry.\n\nStep 3: Verdict and Action\nThe problem is deemed valid. A solution will be provided.\n\nThe analysis proceeds in two parts as requested. First, the selectivity $S$ is computed. Second, the existence of a therapeutic concentration window is evaluated.\n\nPart 1: Computation of Fold-Selectivity\nThe fold-selectivity, $S$, is defined as the ratio of the dissociation constant for the off-target interaction (RBC) to that of the on-target interaction (tumor).\n$$\nS = \\frac{K_{d}^{\\text{RBC}}}{K_{d}^{\\text{tumor}}}\n$$\nSubstituting the given values:\n$$\nS = \\frac{10\\,\\text{nM}}{0.1\\,\\text{nM}} = 100\n$$\nThe selectivity is a dimensionless quantity equal to $100$. This indicates that the molecule binds to the tumor-associated antigen with $100$-fold higher affinity than it binds to CD47 on RBCs.\n\nPart 2: Evaluation of the Therapeutic Window\nThe fractional occupancy, $\\theta$, of a single binding site is described by the Hill-Langmuir equation. For a ligand (drug) $D$, the occupancy of a receptor is given by:\n$$\n\\theta = \\frac{[D]}{[D] + K_{d}}\n$$\nwhere $[D]$ is the free drug concentration and $K_d$ is the dissociation constant for the interaction.\n\nThe problem requires us to determine if there exists a drug concentration $[D]$ that simultaneously satisfies two conditions:\n1. Fractional occupancy on tumor $\\theta_{\\text{tumor}} \\ge 0.9$\n2. Fractional occupancy on RBC $\\theta_{\\text{RBC}} < 0.1$\n\nLet us analyze each condition to find the required range for $[D]$.\n\nCondition for Tumor Occupancy:\nWe require $\\theta_{\\text{tumor}} \\ge 0.9$.\n$$\n\\frac{[D]}{[D] + K_{d}^{\\text{tumor}}} \\ge 0.9\n$$\nSince $[D]$ and $K_{d}^{\\text{tumor}}$ are non-negative, the denominator is positive. We can multiply both sides by $[D] + K_{d}^{\\text{tumor}}$ without changing the inequality direction.\n$$\n[D] \\ge 0.9([D] + K_{d}^{\\text{tumor}})\n$$\n$$\n[D] \\ge 0.9[D] + 0.9 K_{d}^{\\text{tumor}}\n$$\n$$\n0.1[D] \\ge 0.9 K_{d}^{\\text{tumor}}\n$$\n$$\n[D] \\ge 9 K_{d}^{\\text{tumor}}\n$$\nSubstituting the given value $K_{d}^{\\text{tumor}} = 0.1\\,\\text{nM}$:\n$$\n[D] \\ge 9 \\times (0.1\\,\\text{nM})\n$$\n$$\n[D] \\ge 0.9\\,\\text{nM}\n$$\nThis inequality defines the minimum concentration required for therapeutic efficacy.\n\nCondition for RBC Occupancy:\nWe require $\\theta_{\\text{RBC}} < 0.1$.\n$$\n\\frac{[D]}{[D] + K_{d}^{\\text{RBC}}} < 0.1\n$$\nAgain, the denominator is positive.\n$$\n[D] < 0.1([D] + K_{d}^{\\text{RBC}})\n$$\n$$\n[D] < 0.1[D] + 0.1 K_{d}^{\\text{RBC}}\n$$\n$$\n0.9[D] < 0.1 K_{d}^{\\text{RBC}}\n$$\n$$\n[D] < \\frac{0.1}{0.9} K_{d}^{\\text{RBC}} = \\frac{1}{9} K_{d}^{\\text{RBC}}\n$$\nSubstituting the given value $K_{d}^{\\text{RBC}} = 10\\,\\text{nM}$:\n$$\n[D] < \\frac{1}{9} \\times (10\\,\\text{nM})\n$$\n$$\n[D] < \\frac{10}{9}\\,\\text{nM}\n$$\nNumerically, $\\frac{10}{9} \\approx 1.11\\,\\text{nM}$. This inequality defines the maximum concentration to maintain an acceptable safety profile regarding anemia.\n\nExistence of a Therapeutic Window:\nA therapeutic window exists if there is a non-empty set of concentrations $[D]$ that satisfies both derived conditions. We must find if there exists a $[D]$ such that:\n$$\n0.9\\,\\text{nM} \\le [D] < \\frac{10}{9}\\,\\text{nM}\n$$\nSince $0.9 = \\frac{8.1}{9}$, the inequality is:\n$$\n\\frac{8.1}{9}\\,\\text{nM} \\le [D] < \\frac{10}{9}\\,\\text{nM}\n$$\nThis interval is non-empty. For example, a concentration of $[D] = 1.0\\,\\text{nM}$ satisfies both conditions, as $0.9 \\le 1.0 < 1.11...$.\nTherefore, a therapeutic concentration window does exist.\n\nConsequences for Dosing:\nThe existence of this window, $[0.9\\,\\text{nM}, \\frac{10}{9}\\,\\text{nM})$, means it is theoretically possible to dose the bispecific molecule to be effective against the tumor while limiting toxicity to RBCs. However, this therapeutic window is extremely narrow. The upper bound is only $(\\frac{10}{9}) / 0.9 \\approx 1.23$ times, or $23\\%$, larger than the lower bound. Such a narrow window presents a significant clinical challenge. Minor patient-to-patient variability in pharmacokinetics, or fluctuations in an individual's drug metabolism, could easily result in plasma concentrations falling outside this range. Concentrations below $0.9\\,\\text{nM}$ would be inefficacious, while concentrations above $\\frac{10}{9}\\,\\text{nM}$ would lead to unacceptable levels of erythrophagocytosis and anemia. This necessitates extremely precise dosing regimens, and likely therapeutic drug monitoring, to ensure the drug concentration is maintained within this tight boundary. A higher selectivity $S$ would widen this window, making the drug safer and easier to administer.", "answer": "$$\\boxed{100}$$", "id": "2865629"}]}